JP2008509187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509187A5 JP2008509187A5 JP2007525252A JP2007525252A JP2008509187A5 JP 2008509187 A5 JP2008509187 A5 JP 2008509187A5 JP 2007525252 A JP2007525252 A JP 2007525252A JP 2007525252 A JP2007525252 A JP 2007525252A JP 2008509187 A5 JP2008509187 A5 JP 2008509187A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- benzamide
- trifluoromethyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- LKTXZPVKQYEMBU-UHFFFAOYSA-N 3-(1,3-benzothiazol-6-yl)-4-methyl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3SC=NC3=CC=2)C(C)=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 LKTXZPVKQYEMBU-UHFFFAOYSA-N 0.000 claims 1
- XHEISHRKUMLZES-UHFFFAOYSA-N 3-isoquinolin-7-yl-4-methyl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3C=NC=CC3=CC=2)C(C)=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 XHEISHRKUMLZES-UHFFFAOYSA-N 0.000 claims 1
- HRJNAQDUSGCBOJ-UHFFFAOYSA-N 3-isoquinolin-7-yl-4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C=2C=C3C=NC=CC3=CC=2)=C1 HRJNAQDUSGCBOJ-UHFFFAOYSA-N 0.000 claims 1
- SQNGPSFWLCMUMK-UHFFFAOYSA-N 4-[(4-methylpiperazin-1-yl)methyl]-n-(4-methyl-3-quinazolin-6-ylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(C(C)=CC=2)C=2C=C3C=NC=NC3=CC=2)C=C1C(F)(F)F SQNGPSFWLCMUMK-UHFFFAOYSA-N 0.000 claims 1
- OWMQRYCHOXSPEK-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-n-(3-isoquinolin-7-yl-4-methylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(CN(C)C)=CC=C1C(=O)NC1=CC=C(C)C(C=2C=C3C=NC=CC3=CC=2)=C1 OWMQRYCHOXSPEK-UHFFFAOYSA-N 0.000 claims 1
- VLTMZUJBRIXLPY-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-n-(4-methyl-3-phthalazin-6-ylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(CN(C)C)=CC=C1C(=O)NC1=CC=C(C)C(C=2C=C3C=NN=CC3=CC=2)=C1 VLTMZUJBRIXLPY-UHFFFAOYSA-N 0.000 claims 1
- QJKQUQSBZCHWKL-UHFFFAOYSA-N 4-methyl-3-phthalazin-6-yl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 QJKQUQSBZCHWKL-UHFFFAOYSA-N 0.000 claims 1
- KEJIZGVSPJNUSG-UHFFFAOYSA-N 4-methyl-3-phthalazin-6-yl-n-[4-(piperidin-1-ylmethyl)-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1C(=O)NC(C=C1C(F)(F)F)=CC=C1CN1CCCCC1 KEJIZGVSPJNUSG-UHFFFAOYSA-N 0.000 claims 1
- KKVXPGXEJSXINH-UHFFFAOYSA-N 4-methyl-3-phthalazin-6-yl-n-[4-(pyrrolidin-1-ylmethyl)-3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1C(=O)NC(C=C1C(F)(F)F)=CC=C1CN1CCCC1 KKVXPGXEJSXINH-UHFFFAOYSA-N 0.000 claims 1
- VZGDGFQDMARMNX-UHFFFAOYSA-N 4-methyl-3-quinazolin-6-yl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(C=2C=C3C=NC=NC3=CC=2)C(C)=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 VZGDGFQDMARMNX-UHFFFAOYSA-N 0.000 claims 1
- DOOUPYSMBGVLED-UHFFFAOYSA-N 4-methyl-n-[4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)phenyl]-3-phthalazin-6-ylbenzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1C(=O)NC(C=C1C(F)(F)F)=CC=C1CN1CCOCC1 DOOUPYSMBGVLED-UHFFFAOYSA-N 0.000 claims 1
- YQMNZIMHJHNUIM-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-phthalazin-6-ylbenzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C=2C=C3C=NN=CC3=CC=2)=C1 YQMNZIMHJHNUIM-UHFFFAOYSA-N 0.000 claims 1
- NZOOIVRJLWIOIG-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-quinazolin-6-ylbenzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C=2C=C3C=NC=NC3=CC=2)=C1 NZOOIVRJLWIOIG-UHFFFAOYSA-N 0.000 claims 1
- -1 4-methyl-piperazin-1-ylmethyl Chemical group 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 claims 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 claims 1
- 102000001332 SRC Human genes 0.000 claims 1
- 108060006706 SRC Proteins 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 150000001642 boronic acid derivatives Chemical class 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- WUCLNFFXNHSKFY-UHFFFAOYSA-N n-(3-isoquinolin-7-yl-4-methylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NC=CC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 WUCLNFFXNHSKFY-UHFFFAOYSA-N 0.000 claims 1
- WEZAETNOOOWBEV-UHFFFAOYSA-N n-(3-isoquinolin-7-yl-4-methylphenyl)-4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NC=CC3=CC=2)C(C)=CC=C1NC(=O)C(C=C1C(F)(F)F)=CC=C1CN1CCOCC1 WEZAETNOOOWBEV-UHFFFAOYSA-N 0.000 claims 1
- RDNJSLLWQJDVAN-UHFFFAOYSA-N n-(3-isoquinolin-7-yl-4-methylphenyl)-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(C(C)=CC=2)C=2C=C3C=NC=CC3=CC=2)C=C1C(F)(F)F RDNJSLLWQJDVAN-UHFFFAOYSA-N 0.000 claims 1
- HUEBBWXHQRJQBA-UHFFFAOYSA-N n-(4-methyl-3-phthalazin-6-ylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 HUEBBWXHQRJQBA-UHFFFAOYSA-N 0.000 claims 1
- JNANTAFLVVZBSS-UHFFFAOYSA-N n-(4-methyl-3-phthalazin-6-ylphenyl)-4-(morpholin-4-ylmethyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1NC(=O)C(C=C1C(F)(F)F)=CC=C1CN1CCOCC1 JNANTAFLVVZBSS-UHFFFAOYSA-N 0.000 claims 1
- PSRLFLMSZFBATQ-UHFFFAOYSA-N n-(4-methyl-3-phthalazin-6-ylphenyl)-4-(piperidin-1-ylmethyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NN=CC3=CC=2)C(C)=CC=C1NC(=O)C(C=C1C(F)(F)F)=CC=C1CN1CCCCC1 PSRLFLMSZFBATQ-UHFFFAOYSA-N 0.000 claims 1
- ISHGNBGFTLNSCV-UHFFFAOYSA-N n-(4-methyl-3-phthalazin-6-ylphenyl)-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(C(C)=CC=2)C=2C=C3C=NN=CC3=CC=2)C=C1C(F)(F)F ISHGNBGFTLNSCV-UHFFFAOYSA-N 0.000 claims 1
- YBHJIMYXLDSGSR-UHFFFAOYSA-N n-(4-methyl-3-quinazolin-6-ylphenyl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3C=NC=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 YBHJIMYXLDSGSR-UHFFFAOYSA-N 0.000 claims 1
- GSDDFQPXMDVYOD-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-5-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3N=CSC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 GSDDFQPXMDVYOD-UHFFFAOYSA-N 0.000 claims 1
- BQNIEYQHHPDLJI-UHFFFAOYSA-N n-[3-(1,3-benzothiazol-6-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C=2C=C3SC=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 BQNIEYQHHPDLJI-UHFFFAOYSA-N 0.000 claims 1
- JWCFBQGDEABLIJ-UHFFFAOYSA-N n-[3-(2-aminoquinazolin-6-yl)-4-methylphenyl]-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(C(C)=CC=2)C=2C=C3C=NC(N)=NC3=CC=2)C=C1C(F)(F)F JWCFBQGDEABLIJ-UHFFFAOYSA-N 0.000 claims 1
- DMXWAOUYXWLNOD-UHFFFAOYSA-N n-[4-[(dimethylamino)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-phthalazin-6-ylbenzamide Chemical compound C1=C(C(F)(F)F)C(CN(C)C)=CC=C1NC(=O)C1=CC=C(C)C(C=2C=C3C=NN=CC3=CC=2)=C1 DMXWAOUYXWLNOD-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 0 CC1=C(B(*)*)*=C(*c2cc(C(F)(F)F)c(*)c(*)c2)CC1 Chemical compound CC1=C(B(*)*)*=C(*c2cc(C(F)(F)F)c(*)c(*)c2)CC1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0417905.7A GB0417905D0 (en) | 2004-08-11 | 2004-08-11 | Organic compounds |
| PCT/EP2005/008695 WO2006015859A1 (en) | 2004-08-11 | 2005-08-10 | Trifluoromethyl substituted benzamides as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509187A JP2008509187A (ja) | 2008-03-27 |
| JP2008509187A5 true JP2008509187A5 (enExample) | 2008-10-02 |
Family
ID=33017336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525252A Pending JP2008509187A (ja) | 2004-08-11 | 2005-08-10 | キナーゼ阻害剤としてのトリフルオロメチル置換ベンズアミド |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20080096883A1 (enExample) |
| EP (1) | EP1778640A1 (enExample) |
| JP (1) | JP2008509187A (enExample) |
| KR (1) | KR20070046851A (enExample) |
| CN (2) | CN101039914A (enExample) |
| AU (1) | AU2005270313A1 (enExample) |
| BR (1) | BRPI0514288A (enExample) |
| CA (1) | CA2575316A1 (enExample) |
| EC (1) | ECSP077235A (enExample) |
| GB (1) | GB0417905D0 (enExample) |
| IL (1) | IL181169A0 (enExample) |
| MA (1) | MA28822B1 (enExample) |
| MX (1) | MX2007001642A (enExample) |
| NO (1) | NO20071300L (enExample) |
| RU (1) | RU2007108861A (enExample) |
| TN (1) | TNSN07048A1 (enExample) |
| WO (1) | WO2006015859A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054916A1 (en) † | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| BRPI0709749A2 (pt) * | 2006-04-05 | 2011-07-26 | Novartis Ag | combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer |
| AU2007272533A1 (en) * | 2006-07-13 | 2008-01-17 | Novartis Ag | Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders |
| WO2008009077A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| AU2007293065B2 (en) * | 2006-09-05 | 2011-08-18 | Amgen Inc. | Phthalazine, AZA- and diaza-phthalazine compounds and methods of use |
| WO2008077064A2 (en) * | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Biomarker identifying the reactivation of stat3 after src inhibition |
| US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
| CA2685597C (en) * | 2007-05-07 | 2012-10-02 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use |
| CA2685674C (en) * | 2007-05-07 | 2012-07-17 | Amgen Inc. | Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use |
| US20100292292A1 (en) * | 2007-09-13 | 2010-11-18 | Link Medicine Corporation | Treatment of Neurodegenerative Diseases Using Indatraline Analogs |
| US8367671B2 (en) * | 2008-03-21 | 2013-02-05 | Amgen Inc. | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents |
| WO2009131173A1 (ja) | 2008-04-23 | 2009-10-29 | 協和発酵キリン株式会社 | 2-アミノキナゾリン誘導体 |
| US8455495B2 (en) | 2008-08-29 | 2013-06-04 | Amgen Inc. | Pyridazino-pyridinone compounds and methods of use |
| EP2334673A1 (en) | 2008-08-29 | 2011-06-22 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| WO2010042649A2 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF |
| WO2010042646A1 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof |
| WO2010096395A1 (en) * | 2009-02-18 | 2010-08-26 | Syntech Solution Llc | Amides as kinase inhibitors |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| CA2765044A1 (en) | 2009-06-09 | 2010-12-16 | California Capital Equity, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
| CN102573480B (zh) | 2009-06-09 | 2015-06-10 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| EA201290255A1 (ru) * | 2009-10-30 | 2013-04-30 | Ариад Фармасьютикалз, Инк. | Способы и композиции для лечения рака |
| CN102675289B (zh) * | 2011-03-18 | 2014-11-05 | 浙江大德药业集团有限公司 | 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物 |
| WO2012148792A1 (en) * | 2011-04-26 | 2012-11-01 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as b-raf inhibitors for treatment of cancer |
| KR102394917B1 (ko) | 2015-03-04 | 2022-05-09 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| PT3507276T (pt) | 2016-09-02 | 2022-01-11 | Gilead Sciences Inc | Compostos moduladores do recetor de tipo toll |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| CN111904960A (zh) * | 2020-05-19 | 2020-11-10 | 合肥合源药业有限公司 | 一种固体分散体及药用组合物 |
| KR102463217B1 (ko) * | 2020-07-13 | 2022-11-07 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| CN111925331A (zh) * | 2020-07-14 | 2020-11-13 | 上海毕得医药科技有限公司 | 一种6-溴酞嗪的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6587829B1 (en) * | 1997-07-31 | 2003-07-01 | Schering Corporation | Method and apparatus for improving patient compliance with prescriptions |
| US6523009B1 (en) * | 1999-11-06 | 2003-02-18 | Bobbi L. Wilkins | Individualized patient electronic medical records system |
| US20030236682A1 (en) * | 1999-11-08 | 2003-12-25 | Heyer Charlette L. | Method and system for managing a healthcare network |
| US6684276B2 (en) * | 2001-03-28 | 2004-01-27 | Thomas M. Walker | Patient encounter electronic medical record system, method, and computer product |
| GB0217757D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
-
2004
- 2004-08-11 GB GBGB0417905.7A patent/GB0417905D0/en not_active Ceased
-
2005
- 2005-08-10 BR BRPI0514288-1A patent/BRPI0514288A/pt not_active IP Right Cessation
- 2005-08-10 MX MX2007001642A patent/MX2007001642A/es not_active Application Discontinuation
- 2005-08-10 JP JP2007525252A patent/JP2008509187A/ja active Pending
- 2005-08-10 EP EP05777531A patent/EP1778640A1/en not_active Withdrawn
- 2005-08-10 WO PCT/EP2005/008695 patent/WO2006015859A1/en not_active Ceased
- 2005-08-10 AU AU2005270313A patent/AU2005270313A1/en not_active Abandoned
- 2005-08-10 RU RU2007108861/04A patent/RU2007108861A/ru not_active Application Discontinuation
- 2005-08-10 US US11/573,235 patent/US20080096883A1/en not_active Abandoned
- 2005-08-10 US US11/201,348 patent/US20060035897A1/en not_active Abandoned
- 2005-08-10 KR KR1020077003238A patent/KR20070046851A/ko not_active Withdrawn
- 2005-08-10 CA CA002575316A patent/CA2575316A1/en not_active Abandoned
- 2005-08-10 CN CNA200580034662XA patent/CN101039914A/zh active Pending
- 2005-08-10 CN CN200910175026A patent/CN101696188A/zh active Pending
-
2007
- 2007-02-05 IL IL181169A patent/IL181169A0/en unknown
- 2007-02-09 TN TNP2007000048A patent/TNSN07048A1/en unknown
- 2007-02-09 EC EC2007007235A patent/ECSP077235A/es unknown
- 2007-02-22 MA MA29711A patent/MA28822B1/fr unknown
- 2007-03-09 NO NO20071300A patent/NO20071300L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509187A5 (enExample) | ||
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| JP2005519908A5 (enExample) | ||
| JP2009507909A5 (enExample) | ||
| JP2004525179A5 (enExample) | ||
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| JP2006500370A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2005536475A5 (enExample) | ||
| PT2420491E (pt) | Compostos de piperidina 3,5-substituída como inibidores de renina | |
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| MXPA01006474A (es) | Derivados colquinol como agentes perjudiciales vasculares. | |
| JP2010513434A5 (enExample) | ||
| RU2003121307A (ru) | (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета | |
| JP2007507494A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JPH0422889B2 (enExample) | ||
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| JP2005508872A5 (enExample) | ||
| JP2005532397A5 (enExample) | ||
| EA019037B1 (ru) | 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1 | |
| JP2014504648A5 (enExample) | ||
| JP2004536079A5 (enExample) | ||
| JP2015526475A5 (enExample) |